Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(17 sites)
Australia
Research Site 2, Liverpool, New South Wales Research Site 3, Auchenflower, Queensland Research Site 1, Birtinya, Queensland Research Site 4, Melbourne, Victoria Canada
Research Site 2, Calgary, Alberta Research Site 3, Edmonton, Alberta Research Site 1, Montreal, Quebec New Zealand
Research Site 1, Auckland Spain
Research Site 3, Barcelona Research Site 1, Valencia